You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Colorcon
Moodys
Express Scripts
Baxter

Last Updated: May 6, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR RECLAST

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Reclast

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00171964 Efficacy and Tolerability of Zoledronic Acid With Radiotherapy in Pts With Advanced Osteolytic Bone Lesions Completed Novartis Pharmaceuticals Phase 4 2002-05-01 It is the aim of this multicentric clinical study to assess the efficacy and tolerability of zoledronic acid in combination with radiotherapy in patients with advanced osteolytic bone lesions in terms of the reduction of pain and analgesic consumption.
NCT00439647 Efficacy in Reducing Fractures and Safety of Zoledronic Acid in Men With Osteoporosis Completed Novartis Pharmaceuticals Phase 3 2006-12-01 This study will investigate if the drug zoledronic acid given once yearly is safe and has beneficial effects in treating osteoporosis by reducing bone loss and fractures in men with osteoporosis.
NCT00558012 Zoledronic Acid for Osteoporosis in the Elderly Completed National Institute on Aging (NIA) N/A 2007-12-01 This trial will examine the safety, efficacy and feasibility of a single dose of intravenous zoledronic acid in the maintenance of skeletal integrity for frail, institutionalized women, who are most at risk for the deleterious outcomes of osteoporosis. The investigators will test the hypothesis that in institutionalized elderly women a single dose of intravenous zoledronic acid therapy will: (1) be efficacious as demonstrated by stability or improvement in bone mass measurements and reductions in bone turnover; (2) be safe and feasible; and (3) provide estimates for vertebral and nonvertebral fracture reduction in this cohort for use in planning a future study.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Reclast

Condition Name

Condition Name for Reclast
Intervention Trials
Osteoporosis 4
Bone Loss 3
Paget's Disease of the Bone 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Reclast
Intervention Trials
Osteoporosis 7
Bone Diseases, Metabolic 2
Osteitis Deformans 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Reclast

Trials by Country

Trials by Country for Reclast
Location Trials
United States 13
Australia 3
Germany 2
Spain 2
United Kingdom 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Reclast
Location Trials
Georgia 2
Pennsylvania 2
Nebraska 2
Wisconsin 1
Texas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Reclast

Clinical Trial Phase

Clinical Trial Phase for Reclast
Clinical Trial Phase Trials
Phase 4 6
Phase 3 1
Phase 2 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Reclast
Clinical Trial Phase Trials
Completed 7
Not yet recruiting 3
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Reclast

Sponsor Name

Sponsor Name for Reclast
Sponsor Trials
Novartis Pharmaceuticals 5
National Institute on Aging (NIA) 2
University of Pittsburgh 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Reclast
Sponsor Trials
Other 11
Industry 7
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Medtronic
Harvard Business School
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.